EPS CAGR:-41.23%(TTM)
EPS CAGR uses precomputed diluted earnings history where available.
Over longer horizons, EPS CAGR averages 275.38% over 3 years and 99.91% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. EPS (Earnings Per Share) CAGR measures how the company's earnings per share have grown. This is a key metric for valuation and reflects profitability on a per-share basis.
PODD EPS CAGR Chart
Insulet Corp. (PODD)
PODD Quarterly EPS Growth (YoY)
EPS growth vs the same quarter one year earlier, last 20 quarters.
PODD EPS CAGR History
| Year | Start EPS | End EPS | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $5.97 | $3.51 | $-2.46 | -41.21% | -41.21% |
| 2024 | $2.96 | $5.97 | +$3.01 | +101.69% | +101.69% |
| 2023 | $0.07 | $2.96 | +$2.89 | +4364.56% | +4364.56% |
| 2022 | $0.25 | $0.07 | $-0.18 | -73.48% | -73.48% |
| 2021 | $0.11 | $0.25 | +$0.14 | +127.27% | +127.27% |
| 2020 | $0.19 | $0.11 | $-0.08 | -42.11% | -42.11% |
| 2019 | $0.06 | $0.19 | +$0.13 | +239.89% | +239.89% |
| 2018 | $-0.46 | $0.06 | +$0.52 | N/A | N/A |
| 2017 | $-0.51 | $-0.46 | +$0.05 | N/A | N/A |
| 2016 | $-1.29 | $-0.51 | +$0.78 | N/A | N/A |
| 2015 | $-0.93 | $-1.29 | $-0.36 | N/A | N/A |
| 2014 | $-0.83 | $-0.93 | $-0.10 | N/A | N/A |
| 2013 | $-1.08 | $-0.83 | +$0.25 | N/A | N/A |
| 2012 | $-1.22 | $-1.08 | +$0.14 | N/A | N/A |
| 2011 | $-1.54 | $-1.22 | +$0.32 | N/A | N/A |
| 2010 | $-2.68 | $-1.54 | +$1.14 | N/A | N/A |
| 2009 | $-3.36 | $-2.68 | +$0.68 | N/A | N/A |
| 2008 | $-3.21 | $-3.36 | $-0.15 | N/A | N/A |
| 2007 | $-99.10 | $-3.21 | +$95.89 | N/A | N/A |
| 2006 | $-70.95 | $-99.10 | $-28.15 | N/A | N/A |
| 2005 | $-47.64 | $-70.95 | $-23.31 | N/A | N/A |
| 2004 | $-43.88 | $-47.64 | $-3.76 | N/A | N/A |
| 2003 | $-42.30 | $-43.88 | $-1.58 | N/A | N/A |
Quarterly EPS: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $1.30 | -10.3% | +160.0% |
| Q4 2025 | $1.45 | +16.9% | +0.7% |
| Q3 2025 | $1.24 | +287.5% | +11.7% |
| Q2 2025 | $0.32 | -36.0% | -88.1% |
| Q1 2025 | $0.50 | -65.3% | -32.4% |
| Q4 2024 | $1.44 | +29.7% | -2.7% |
| Q3 2024 | $1.11 | -58.7% | +50.0% |
| Q2 2024 | $2.69 | +263.5% | +589.7% |
| Q1 2024 | $0.74 | -50.0% | +117.6% |
| Q4 2023 | $1.48 | +100.0% | +492.0% |
| Q3 2023 | $0.74 | +89.7% | — |
| Q2 2023 | $0.39 | +14.7% | — |
| Q1 2023 | $0.34 | +36.0% | -15.0% |
| Q4 2022 | $0.25 | — | -40.5% |
| Q3 2022 | $-0.07 | +85.0% | — |
| Q2 2022 | $-0.50 | — | -35.1% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy